» Authors » Laura Conforti

Laura Conforti

Explore the profile of Laura Conforti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 69
Citations 2343
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Chimote A, Lehn M, Bhati J, Mascia A, Sertorio M, Lamba M, et al.
Cancers (Basel) . 2024 Mar; 16(5). PMID: 38473367
Proton therapy (PT) is emerging as an effective and less toxic alternative to conventional X-ray-based photon therapy (XRT) for patients with advanced head and neck squamous cell carcinomas (HNSCCs) owing...
2.
Chimote A, Alshwimi A, Chirra M, Gawali V, Powers-Fletcher M, Hudock K, et al.
Front Immunol . 2023 Apr; 14:1143350. PMID: 37033961
Introduction: Severe COVID-19 is characterized by cytokine storm, an excessive production of proinflammatory cytokines that contributes to acute lung damage and death. Dexamethasone is routinely used to treat severe COVID-19...
3.
Chirra M, Newton H, Gawali V, Wise-Draper T, Chimote A, Conforti L
Cancers (Basel) . 2022 Jul; 14(15). PMID: 35892822
Competent antitumor immune cells are fundamental for tumor surveillance and combating active cancers. Once established, tumors generate a tumor microenvironment (TME) consisting of complex cellular and metabolic elements that serve...
4.
Gawali V, Chimote A, Newton H, Feria-Garzon M, Chirra M, Janssen E, et al.
Front Pharmacol . 2021 Sep; 12:742862. PMID: 34512366
Programmed death receptor-1 (PD-1) and its ligand (PD-L1) interaction negatively regulates T cell function in head and neck squamous cell carcinoma (HNSCC). Overexpression of PD-1 reduces intracellular Ca fluxes, and...
5.
Newton H, Chimote A, Arnold M, Wise-Draper T, Conforti L
Mol Ther Methods Clin Dev . 2021 Apr; 21:133-143. PMID: 33816646
In solid malignancies, including head and neck squamous cell carcinoma (HNSCC), the immunosuppressive molecule adenosine, which accumulates in the tumor, suppresses cytotoxic CD8 T cell functions including chemotaxis and tumor...
6.
Khodoun M, Chimote A, Ilyas F, Duncan H, Moncrieffe H, Kant K, et al.
Sci Adv . 2020 Nov; 6(47). PMID: 33208373
Lupus nephritis (LN) is an autoimmune disease with substantial morbidity/mortality and limited efficacy of available therapies. Memory T (Tm) lymphocytes infiltrate LN kidneys, contributing to organ damage. Analysis of LN,...
7.
Newton H, Gawali V, Chimote A, Lehn M, Palackdharry S, Hinrichs B, et al.
J Immunother Cancer . 2020 Oct; 8(2). PMID: 33060146
Background: Immunotherapy has emerged as a promising treatment modality for head and neck squamous cell carcinoma (HNSCC). Pembrolizumab, an anti-programmed death 1 antibody, is an immunotherapy agent currently approved for...
8.
Dirar Q, Russell T, Liu L, Ahn S, Dotti G, Aravamudhan S, et al.
PLoS One . 2020 Sep; 15(9):e0238819. PMID: 32976541
Adoptive cell transfer of Chimeric Antigen Receptor (CAR)-T cells showed promising results in patients with B cell malignancies. However, the detailed mechanism of CAR-T cell interaction with the target tumor...
9.
Agresta L, Lehn M, Lampe K, Cantrell R, Hennies C, Szabo S, et al.
J Immunother Cancer . 2020 Mar; 8(1). PMID: 32217758
Background: Developing novel strategies to overcome the immunosuppressive tumor microenvironment is a critically important area of cancer therapy research. Here, we assess the therapeutic potential of CD244 (2B4/signaling lymphocyte activation...
10.
Chimote A, Gawali V, Newton H, Wise-Draper T, Conforti L
Front Pharmacol . 2020 Mar; 11:143. PMID: 32184726
The limited ability of cytotoxic CD8 T cells to infiltrate solid tumors and function within the tumor microenvironment presents a major roadblock to effective immunotherapy. Ion channels and Ca-dependent signaling...